Anticlotting Medicine Lowers Incidence of Heart Attack

New data shows anticlotting medicine Tirofiban (AGGRASTAT®) lowers incidence of heart attack in patients who respond poorly to aspirin or Clopidogrel after elective coronary angioplasty. Dr Marco Valgimigli, Chair of Cardiology, University of Ferrara, Italy and the principal investigator of the study emphasised the significance of the findings as they “Demonstrate a proof of concept for a new treatment strategy in a patient segment whose needs have so far remained unaddressed.”